Hutch News
Results per Page:
New Science Spotlight Articles
Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
January 20, 2020
Failed Alzheimer’s drug boosts CAR T-cell therapy
Engineered immune cells get a helping hand in new clinical trial for multiple myeloma patients
Fred Hutch adds senior leaders from Celgene and Amazon to board of trustees
Dr. Corsee Sanders and Sean Boyle add science, technology, finance and innovation expertise to cancer research center’s board
Forum at Fred Hutch focuses on the hottest developments in cancer immunotherapy
Immune-based treatments move from the fringes to the spotlight
Inaugural 'Oncology Summit' addresses academic-industry partnerships
Fred Hutch, Merck co-host inaugural ‘Oncology Summit’ to capture non-profit and for-profit outlooks on cancer care
DeFeatHIV receives second five-year grant from NIH to research gene and cell therapies
The funding allows Fred Hutch’s HIV cure program to both extend and expand
Many immunotherapy trial participants with blood cancer in remission, preliminary results show
High rates of complete remission reported in patients with advanced blood cancers in preliminary results from ongoing immunotherapy trial
Immunotherapy for pancreatic cancer boosts survival more than 75 percent in mice, study finds
Therapy using engineered immune cells offers promise for the ‘disease that desperately needs something new’
Immunotherapy for pancreatic cancer boosts survival by more than 75% in mice
Human trials are planned within the next year
Why cancer research needs business development – now more than ever
Meet Fred Hutch’s Dr. Niki Robinson, the woman who’s helping make it happen
'A tidal wave coming': Xconomy Forum focuses on promising treatments
Immunotherapy a key topic at sold-out discussion on the role of biotech in Seattle
Three cancer research powerhouses form immunotherapy startup
Fred Hutch, Memorial Sloan-Kettering and Seattle Children’s Research Institute join to launch Juno Therapeutics